BRAF and neoplasm: Because BRAF inhibitor resistance in BRAF V600E melanoma is associated with an immunosuppressed tumor microenvironment and consequent tumor immune evasion [24] we tested all three isogenic melanoma models for increased levels of cell-surface PD-L1 expression by flow cytometry (Figure 6A).